Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Celgene pens pact to join Bristol-Myers, Pfizer in R&D race

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 12:18pm CET

Celgene has secured an option on two preclinical assets in development at Nimbus Therapeutics. The deal gives Celgene a chance to move into the slipstreams of Bristol-Myers Squibb and Pfizer in the race to bring a TYK2 inhibitor to market.

TYK2 has attracted the interest of multiple major research groups on the strength of its role in the inflammatory response. Bristol-Myers has advanced its shot at the target, BMS-986165, into phase 2 trials in lupus and psoriasis. Pfizer is testing its TYK2-JAK1 kinase inhibitor, PF-06700841, in three phase 2 trials, which are enrolling patients with alopecia areata, ulcerative colitis and psoriasis.

Nimbus program has ceded a sizable head start to these drugs, but Celgene has seen enough in the preclinical data to suggest it can come from behind. That confidence is based, in part, on evidence Nimbus inhibitors are particularly selective for TYK2, enabling them to hit the target but not its JAK siblings.

The importance of TYK2 means there are plenty of opportunities to go around, too. A TYK2 inhibitor could treat autoimmune conditions including rheumatoid arthritis, Crohns disease and multiple sclerosis, as well as the indications being pursued in the clinic by Bristol-Myers and Pfizer.

We are excited about the potential of the Nimbus immunology targets, which are based on compelling human genetic data, Celgene R&D VP Robert Plenge, M.D., Ph.D., said in a statement. Moreover, Nimbus robust in silico-based approach is very promising.

That prompted the prolific dealmaker to put together an agreement that gives it an option to buy the program for an as-yet-undisclosed upfront payment and downstream milestones. The release of clinical trial data will trigger the buy-in decision on the TYK2 program and other assets covered by the deal. Nimbus is in charge of advancing the assets until Celgene exercises its option.

The second asset covered by the agreement is designed to block STING from activating the innate immune system in interferonopathies such as lupus. Nimbus agreement leaves it free to develop a small molecule agonist program with applications in immuno-oncology.

That immuno-oncology program is the only publicly disclosed part of Nimbus pipeline that is not yet the subject of a deal. Gilead and Genentech have already picked off other parts of the pipeline through an acquisition and licensing deal, respectively.

(c) 2017 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
12/14 CELGENE : DE/ Submission of Matters to a Vote of Security Holders (form 8-K/A)
12/14 CELGENE : Launches Celgene Cancer Care Links TM to Support Cancer Healthcare Cap..
12/14 CELGENE : Long-Term Efficacy Data from the Phase III GeparSepto Study in High Ri..
12/13 JUNO THERAPEUTICS : and Celgene Corporation Release Additional Data from TRANSCE..
12/13 JUNO THERAPEUTICS : and Celgene Corporation Release Additional Data from TRANSCE..
12/13 JUNO THERAPEUTICS : Highlights Key Translational Insights with JCAR017 in Patien..
12/13 Celgene, Gilead, and Regeneron are On the Mend
12/12 CELGENE CORPORATION : and bluebird bio Announce Updated Results from Ongoing Mul..
12/12 ACCELERON PHARMA : Announces Updated Results from Ongoing Phase 2 Trials of Lusp..
12/12 BEIGENE : falls on immune events for B cell cancer combo
More news
News from SeekingAlpha
12/14 AGIOS PHARMACEUTICALS : Updates To Thesis And A Look Toward 2018
12/14 YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/13 Why Tech Still Looks So Attractive
12/13 YOUR DAILY PHARMA SCOOP : Omeros Potential, Portola's Setback, Proteostasis Soar..
12/12 CUTTING EDGE GENE THERAPIES : Beta-Thalassemia Breakthroughs (Part I)
Financials ($)
Sales 2017 12 967 M
EBIT 2017 7 286 M
Net income 2017 4 215 M
Debt 2017 4 463 M
Yield 2017 -
P/E ratio 2017 20,57
P/E ratio 2018 15,26
EV / Sales 2017 6,92x
EV / Sales 2018 5,71x
Capitalization 85 219 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 125 $
Spread / Average Target 15%
EPS Revisions
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%383 877
NOVARTIS12.01%221 304
PFIZER10.04%218 400
ROCHE HOLDING LTD.3.40%210 833
MERCK AND COMPANY-6.96%155 214